Medicine and Dentistry
Pembrolizumab
100%
Overall Survival
96%
Stereotactic Body Radiation Therapy
75%
Infection
75%
Immunotherapy
52%
Non Small Cell Lung Cancer
50%
Head and Neck Cancer
50%
Clinical Oncology
50%
Transitional Cell Carcinoma
50%
Malignant Neoplasm
41%
Immune Checkpoint Inhibitor
40%
Neoplasm
36%
Bladder
33%
Combination Therapy
31%
Surgery
31%
Clinical Trial
28%
Diseases
28%
Head and Neck Squamous Cell Carcinoma
26%
Targeted Therapy
25%
Patient Population
25%
Squamous Cell Carcinoma
25%
Equivalent Dose
25%
Robot-Assisted Surgery
25%
Oropharynx
25%
Earache
25%
Cervical Lymph Node
25%
Urothelial Cancer
25%
Cisplatin
25%
Wart Virus
25%
Oropharynx Carcinoma
25%
Adjuvant Radiotherapy
25%
Glycon
25%
Bleeding
25%
Clear Cell Renal Cell Carcinoma
25%
Connective Tissue Cancer
25%
Tonsil
25%
Radiosensitizer
25%
Brain Metastasis
25%
Radical Resection
25%
Kidney Cancer
25%
Whole Brain Radiotherapy
25%
Small Cell Lung Cancer
25%
Oncolytic Virotherapy
25%
Muscle Invasive Bladder Cancer
25%
Dyspnea
25%
Plummer-Vinson Syndrome
25%
Odynophagia
25%
Retroperitoneal Lymph Node Dissection
25%
Progression Free Survival
20%
Comorbidity
18%
Keyphrases
Overall Survival
69%
Chemotherapy
54%
Pembrolizumab
50%
Head-and-neck Cancer
50%
Multivariable
47%
National Cancer Database
40%
Upper Tract Urothelial Carcinoma
37%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
32%
Immune Checkpoint Inhibitors
30%
Radiosensitization
25%
Lung Cancer Brain Metastases
25%
Stereotactic Body Radiation Therapy
25%
Patient Demographics
25%
Cisplatin-ineligible
25%
Prognostic Impact
25%
Cancer Patients
25%
Urothelial Carcinoma
25%
Metastatic Non-small Cell Lung Cancer
25%
Metformin
25%
Small Cell Lung Cancer
25%
Biologically Equivalent Dose
25%
Phase II Study
25%
Single Port
25%
Preoperative Chemotherapy
25%
In Situ
25%
Radical Resection
25%
Impact on Patients
25%
Whole Brain Radiation Therapy
25%
Renal Cancer
25%
Real-world Experience
25%
Clinical Oncology
25%
Stereotactic Body Radiotherapy
25%
Oncolytic Viral Therapy
25%
Metastatic Urothelial Carcinoma
25%
Phase II Trial
25%
Confidence Interval
20%
Median Overall Survival
19%
Chemoimmunotherapy
18%
Prognostic Factors
17%
Metastasis
16%
Negative Factors
16%
Few-cycle
15%
Partial Response
15%
HSV-TK
15%
Histology
14%
Kaplan-Meier Analysis
13%
Urethra
12%
Combination Treatment
12%
Primary Carcinoma
12%
Cervical Lymph Node Dissection
12%
Pharmacology, Toxicology and Pharmaceutical Science
Pembrolizumab
100%
Non Small Cell Lung Cancer
75%
Infection
75%
Overall Survival
74%
Head and Neck Cancer
50%
Immune Checkpoint Inhibitor
40%
Chemotherapy
39%
Head and Neck Squamous Cell Carcinoma
26%
Metformin
25%
Radiosensitizing Agent
25%
Oncolytic Virus
25%
Kidney Cancer
25%
Transitional Cell Carcinoma
25%
Virotherapy
25%
Immunotherapy
25%
Progression Free Survival
24%
Comorbidity
12%
Valaciclovir
10%
Disease Exacerbation
10%
Malignant Neoplasm
9%
Chemoradiation Therapy
9%
Retrospective Study
8%
Neoplasm
6%
Kidney Metastasis
6%
Combination Therapy
5%
Monotherapy
5%